Integrating BIA and eGFR for Nutritional Status in Hemodialysis Patients
Launched by UNIVERSITY OF TARTU · Mar 10, 2025
Trial Information
Current as of May 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how two different methods—Bioelectrical Impedance Analysis (BIA) and estimated Glomerular Filtration Rate (eGFR)—can work together to better assess the health and nutritional status of patients who are on hemodialysis due to chronic kidney disease. Many patients undergoing dialysis face issues like malnutrition and muscle loss, but current methods to evaluate their health are often not very effective. By combining these two measurements, the researchers hope to create a more accurate and easy way to monitor patients' nutrition and overall health, which could lead to better treatment options and improved health outcomes.
To participate in this study, you must have chronic kidney disease and have been on hemodialysis for at least six months. Unfortunately, if you are pregnant, breastfeeding, have certain other serious health conditions, have a pacemaker, or have had recent surgery, you won't be eligible to join. If you qualify, you can expect to have non-invasive tests that will help researchers learn more about your body composition and kidney function. This could potentially lead to better management of your health while on dialysis. The trial is currently recruiting participants of all genders, aged between 65 and 74.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Chronic kidney disease Hemodialysis for at least 6 months
- Exclusion Criteria:
- • Pregnancy Lactation Major second pathology Pacemaker Recent surgery
About University Of Tartu
The University of Tartu, located in Estonia, is a prestigious research institution recognized for its commitment to advancing knowledge and innovation in various fields, including medicine and health sciences. As a clinical trial sponsor, the university leverages its extensive academic resources and expertise to conduct rigorous research aimed at improving patient outcomes and contributing to the broader medical community. With a focus on ethical practices, collaboration, and scientific excellence, the University of Tartu is dedicated to fostering groundbreaking studies that address critical health challenges and enhance the understanding of complex medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tartu, Tartumaa, Estonia
Patients applied
Trial Officials
Alastair Forbes, MD
Study Director
University of Tartu
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported